- 01/06/2020
- fycompa® for adjunctive treatment of partial onset seizures launched in china
- 12/23/2019
- u.s. fda approves eisai’s dayvigo™ (lemborexant) for treatment of insomnia in adult patients
- 12/09/2019
- sysmex presents academic report with a view to creating a simple method of diagnosing alzheimer’s disease using blood
- 12/05/2019
- eisai to present new research on eribulin (halaven®) at 42nd annual san antonio breast cancer symposium
- 12/02/2019
- eisai to present latest data on alzheimer’s disease / dementia pipeline at 12th clinical trials on alzheimer’s disease conference
- 12/02/2019
- additional indication for lenvima® (lenvatinib) for differentiated thyroid cancer accepted in china
- 12/02/2019
- eisai china inc. is certified as the “top employers china 2020”
- 12/01/2019
- launch meeting of the third-generation antiepileptic drug of fycompa (perampanel) in china
- 11/26/2019
- eisai china pharmaceutical co., ltd. carried out scholarships and grants program in peking university health science center for 8 consecutive years
- 11/26/2019
- eisai to present latest data on perampanel at 73rd american epilepsy society annual meeting
